Who is on it, and how far along Every drug ChEMBL records acting on FGA, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Protein or peptide 1 Other 4 Approved1 Fibrinolysin, human Fibrinolysin, human SponsorJiangsu Jingze Biopharmaceutical Co., Ltd. ModalityOther ActionInhibitor Open trials1 Phase 34 Plasminogen Plasminogen SponsorNot known ModalityOther ActionHydrolytic enzyme Open trials96 Fibrinogen, human Fibrinogen, human SponsorCorza Medical GmbH ModalityOther ActionExogenous protein Open trials11 Ancrod Ancrod SponsorNot known ModalityOther ActionHydrolytic enzyme Open trials1 Alfimeprase Alfimeprase SponsorARCA Biopharma, Inc. ModalityProtein or peptide ActionHydrolytic enzyme Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 3 of 5 act as: Fibrinogen hydrolytic enzyme; the rest name their own mechanism. Drug Furthest stage Sponsor Modality Action Open trials Fibrinolysin, human Approved Jiangsu Jingze Biopharmaceutical Co., Ltd. OtherInhibitor Fibrinogen inhibitor 1 Plasminogen Phase 3 — OtherHydrolytic enzyme 96 Fibrinogen, human Phase 3 Corza Medical GmbH OtherExogenous protein Fibrinogen exogenous protein 11 Ancrod Phase 3 — OtherHydrolytic enzyme 1 Alfimeprase Phase 3 ARCA Biopharma, Inc. Protein or peptideHydrolytic enzyme 0
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 18 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling Deficits Plasminogen Phase 3 Recruiting Shandong Provincial Hospital Nov 18, 2026 Dose Reduced Alteplase in Managing Intrapleural Sepsis Plasminogen Phase 3 Not yet recruiting Vanderbilt University Medical Center Nov 17, 2026 Pneumatic Displacement With Anti-VEGF and Concomitant rtPA for PCV-related Submacular Hemorrhage Plasminogen Phase 4 Not yet recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine Nov 17, 2026 Stereotactic Aspiration Combined With Tenecteplase for Acute Pontine Hemorrhage Plasminogen Not applicable Recruiting Beijing Tiantan Hospital Nov 16, 2026 Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 Hours Plasminogen Phase 3 Not yet recruiting The First Affiliated Hospital of University of Science and Technology of China Nov 12, 2026 Effectiveness and Safety of TachoSil® Fibrin Sealant Patch for Supporting Dural Sealing Among Adult Inpatients Fibrinogen, human — Recruiting Corza Medical GmbH Nov 10, 2026 Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features Plasminogen Phase 3 Not yet recruiting China National Center for Cardiovascular Diseases Nov 4, 2026 Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours Plasminogen Phase 3 Not yet recruiting Fujian Medical University Union Hospital Nov 3, 2026 A Study Evaluating the Efficacy and Safety of Recombinant Human Truncated Plasmin Injection (JZB32) in Patients With Vitreomacular Traction Fibrinolysin, human Phase 2 Recruiting Jiangsu Jingze Biopharmaceutical Co., Ltd. Nov 2, 2026 INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 Plasminogen Phase 3 Not yet recruiting University of Calgary Oct 30, 2026 Stability of Blood Clotting Products Stored in Emergency Ambulances Under Real-World Conditions Fibrinogen, human — Recruiting Medical University of Graz Jun 15, 2026 Clinical Study on the Safety and Efficacy of Tendon Stem Progenitor Cells Therapy for Rotator Cuff Tears Fibrinogen, human Early phase 1 Not yet recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine Jan 6, 2026 Fibrinogen in Liver Transplant Fibrinogen, human Phase 4 Recruiting Trauma Hemostatis and Oxygenation Research (THOR) Network Dec 5, 2025 NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery Fibrinogen, human Not applicable Recruiting Maria Sklodowska-Curie National Research Institute of Oncology Oct 14, 2025 PS-002 for the Treatment of IgA Nephropathy in Adults Fibrinogen, human Phase 1 / Phase 2 Recruiting Purespring Therapeutics Limited Sep 19, 2025 Characterization and Longitudinal Monitoring of Muscular Phenotype in Patients Admitted to Intensive Care for Sepsis Fibrinogen, human Not applicable Recruiting Centre Hospitalier de Saint-Brieuc Jul 20, 2025 Social Needs Screening and Chronic Diseases Study (WE CARE) Ancrod Not applicable Recruiting University of Massachusetts, Worcester Apr 1, 2025 Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye Fibrinogen, human Phase 3 Not yet recruiting Cambium Bio Limited Mar 31, 2025
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364709 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets